Park Ha Biological Technology Co., Ltd. is a US-listed company in the specialty chemicals industry. Its financial year ends in October.
Loading chart…
Third-party market data · may be delayed
~$2.1
Price-to-sales vs peers
Base case. Range ~$2.1–$11. Sales per share times peers' typical price-to-sales; used only when earnings are negative.
No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.
Park Ha Biological Technology Co., Ltd. valuation: adjust assumptions and compare models →
Park Ha Biological Technology Co. has little or no product revenue yet; it used $0m of cash in the twelve months. The diluted share count is up 17.8% on a year earlier, which dilutes existing holders. It passes 2 of our 3 financial-health checks.
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Park Ha Biological Technology Co., Ltd.'s trailing-twelve-month revenue grew 6.0% year on year, with a free-cash-flow margin of -0.1%. Where it stands out: gross margin of 94.4% ranks 1 of 40 specialty chemicals companies we cover. Where it lags: stock pay as % of revenue of 953.3% ranks 36 of 36 specialty chemicals companies we cover.
Current signal Balance sheet growing far ahead of sales: Total assets grew 93% year over year while revenue grew 6% — the balance sheet is expanding 87 points faster than the business it supports.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for BYAH from the sources we follow. See filings →
We value Park Ha Biological Technology Co., Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.92 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$2.1 ~$3.3–$11 | Included, half weight |
| Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$2.1 ~$2.1–$11 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Park Ha Biological Technology Co., Ltd. with Specialty Chemicals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2025 |
|---|---|
| Share price | $150.00 |
| Market value | $88m |
| + Net debt (− = net cash) | −$4m |
| Enterprise value | $85m |
| Multiples | |
| Price / sales | 35.0x |
| Price / earnings | — |
| Price / free cash flow | — |
| EV / EBITDA | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
No analyst estimates are published for Park Ha Biological Technology Co., Ltd.: too few analysts cover it.
| Calendar year | 2025 | 2026 to date |
|---|---|---|
| Return | ||
| BYAH | −98% | −97% |
| Industry peers (median) | −13% | +6% |
| S&P 500 | +18% | +11% |
| Months that ended higher | ||
| BYAH | 25% | 18% |
| S&P 500 | 75% | 46% |
| Largest fall from a high during the year | ||
| BYAH | −100% | −97% |
| S&P 500 | −19% | −9% |
Worst fall since December 27, 2024: 100% from July 7, 2025 to November 2, 2026. Getting back needed a 854275% gain, and the shares have not yet recovered.
Source: SEC EDGAR filings. Retrieved Invalid Date.
| Period | Revenue (TTM) |
|---|---|
| FY22 Q4 | $1.9M |
| FY23 Q4 | $2.5M |
| FY24 Q4 | $2.4M |
| FY25 Q4 | $2.5M |
Source: SEC EDGAR filings. Retrieved Invalid Date.
| Period | Operating margin (TTM) |
|---|---|
| FY22 Q4 | 10.3% |
| FY23 Q4 | 48.0% |
| FY24 Q4 | 33.3% |
| FY25 Q4 | -956.5% |
Source: SEC EDGAR filings. Retrieved Invalid Date.
| Period | FCF margin (TTM) |
|---|---|
| FY22 Q4 | 74.5% |
| FY23 Q4 | 4.2% |
| FY24 Q4 | 36.7% |
| FY25 Q4 | -0.1% |
| Fiscal year | 2022 Oct 2022 | 2023 Oct 2023 | 2024 Oct 2024 | 2025 Oct 2025 |
|---|---|---|---|---|
| Income | ||||
| Revenue | 2 | 2 | 2 | 3 |
| Gross profit | 1 | 2 | 2 | 2 |
| EBITDA | 0 | 1 | 1 | −24 |
| Operating income | 0 | 1 | 1 | −24 |
| Net income | 0 | 1 | 0 | −24 |
| Diluted EPS | $0.50 | $1.70 | $0.96 | −$41.38 |
| Growth (year on year) | ||||
| Revenue | — | +28.1% | −3.1% | +6.0% |
| EBITDA | — | +427.7% | −32.0% | <−999% |
| Operating income | — | +499.2% | −32.8% | <−999% |
| Net income | — | +345.4% | −43.8% | <−999% |
| Diluted EPS | — | +240.0% | −43.5% | <−999% |
| Margins | ||||
| Gross margin | 73.5% | 87.4% | 91.8% | 94.4% |
| EBITDA margin | 11.9% | 48.8% | 34.3% | −952.1% |
| Operating margin | 10.3% | 48.0% | 33.3% | −956.5% |
| Net margin | 10.0% | 34.6% | 20.1% | −965.0% |
| Free-cash-flow margin | 74.5% | 4.2% | 36.7% | −0.1% |
| Cash flow | ||||
| Cash from operations | 1 | 0 | 1 | 0 |
| Capital spending | 0 | 0 | 0 | 0 |
| Free cash flow | 1 | 0 | 1 | −0 |
| Stock-based pay | — | — | — | 24 |
| Free cash flow after stock pay | — | — | — | −24 |
| Balance sheet | ||||
| Cash | 1 | 1 | 1 | 4 |
| Total debt | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −1 | −1 | −1 | −4 |
| Diluted shares | — | — | — | — |
| Last 12 months unless stated | BYAH | SNES | ZONE | CITR | REFR | YMAT | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $3m | $2m | $3m | $1m | $654232 | $10m | $906m |
| Revenue growth, last 12 months | 6.0% | 13.4% | 64.2% | −26.4% | −46.5% | −43.5% | 5.4% |
| Revenue growth, 3-year average | — | 29.8% | — | 134.1% | −2.9% | — | 0.9% |
| Revenue growth, latest quarter | — | 23.2% | −0.8% | −59.2% | −33.5% | — | 8.3% |
| Gross margin | 94.4% | 66.2% | 37.8% | −5.2% | — | 54.1% | 28.8% |
| Operating margin | −956.5% | −303.7% | <−999% | <−999% | −348.1% | −207.7% | 4.3% |
| Operating margin, 3-year average | — | −353.6% | −711.2% | −992.9% | −210.0% | — | 5.5% |
| Net margin | −965.0% | −294.7% | <−999% | <−999% | −343.9% | −203.2% | 0.8% |
| Cash from operations / revenue | 3.4% | −281.4% | −533.5% | −576.8% | −238.6% | −31.8% | 6.9% |
| Free-cash-flow margin | −0.1% | −283.7% | −534.7% | −579.5% | −238.6% | −33.9% | 4.3% |
| Free-cash-flow margin, 3-year average | — | −342.6% | −248.7% | −301.2% | −148.0% | — | 5.1% |
| Stock pay / revenue | 953.3% | 12.1% | 271.1% | 742.9% | 33.2% | 0.9% | 1.0% |
| Change in share count | 17.8% | 74.4% | — | 93.5% | 1.5% | 3.8% | 0.1% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 6.0% | 6.0% | 19 of 42 |
| Change in growth rate Growth | +9.1pp | +1.3pp | 7 of 42 |
| Gross margin Profitability | 94.4% | 31.5% | 1 of 40 |
| Operating margin Profitability | -956.5% | 3.8% | 37 of 39 |
| Net margin Profitability | -965.0% | 1.7% | 40 of 42 |
| Free-cash-flow margin Cash generation | -0.1% | 4.8% | 27 of 42 |
| Stock pay as % of revenue Cash generation | 953.3% | 1.0% | 36 of 36 |
| Change in share count Balance sheet | 17.8% | 0.0% | 32 of 37 |
| Days sales outstanding Balance sheet | 37 days | 59 days | 5 of 30 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
